Does golimumab extend the spectrum of anti-TNFα inhibitors for inflammatory bowel diseases?

Česká verzia

Authors: M. Lukáš
Authors place of work: Klinické a výzkumné centrum pro střevní záněty, ISCARE a 1. LF UK v Praze a Ústav klinické biochemie a laboratorní diagnostiky, 1. LF UK v Praze
Published in the journal: Gastroent Hepatol 2012; 66(6): 465-469
Category: IBD: Review Article

Summary

Golimumab is a new drug which belongs to class of anti-TNFα inhibitors. This drug was prepared due to unique synthesis from hybridoma cells lines which were derived from transgenic mouse. The specific golimumab synthesis granted its human origin and some favourable pharmacological properties. In PURSUIT study has been shown that golimumab is very effective therapy and induces and maintains a clinical response, clinical remission, mucosal healing and improves the quality of life in patients with moderately to severely active ulcerative colitis. The position of golimumab in clinical practice in patients with ulcerative colitis has to be proved in the next clinical studies.

Key words:
biological therapy – ulcerative colitis – inflammatory bowel diseases

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
22. 11. 2012

Accepted:
10. 12. 2012

Zdroje

1. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. Gastroent Hepatol 2012; 66(1): 12–22.

2. Dignass A, Lindsay JO, Sturm A et al. Second european evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J Crohn Colitis 2012; 6(10): 991–1030.

3. Sandborn W, Feagan BG, Marano CW et al. A phase 2/3 randomized, placebo-controlled double blid study, to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severe active ulcerative colitis. PURSUIT SC. Gastroenterology 2012; 142(5): S161.

4. Rutgeerts P, Feagan BG, Marano C et al. A Phase 3 randomized, placebo controlled, double blind study to evaluate the safety and efficacy of subcutaneous golimumab maintenance therapy in patiens with moderately to severely active ulcerative colitis: PURSUIT – MAINTENANCE. Gut 2012; 44 (Suppl 2): OP 344.

5. Ben-Bassat O, Iacono A, Irwin PS et al. Golimumab for treatment of moderate to severe anti-TNF refractory Crohn´s disease: Open label experience. Gastroenterology 2012; 142(5): S804.

6. Lonberg N. Human antibodies from transgenic animals. Nature Biotechnology 2005; 23(9): 1117–1125.

7. Shealy D, Cai A, Staquet K et al. Characterisation of golimumab, a human monoclonal antibody specific for human tumor necrosis factor. Landes Bioscience 2010; 2(4): 428–439.

8. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with revmatoid arthritis after treatment with tumor necrosis sloha inhibitors (GO-AFTER study): a multicentre, double-blind, randomised placebo-controlled, phase III. Lancet 2009; 374(9685): 210–221.

9. Reinisch W, Sanborn WJ, Holmes DW et al. Adalimumab for induction clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60(6): 780–787.

10. Sandborn W, Van Asche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate – severe ulcerative colitis. Gastroenterology 2012; 142(2): 257–265.

11. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as a rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128(7): 1805–1811.

12. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462–2476